CDC is issuing new guidance to clinicians for the treatment of severe malaria cases in the United States (U.S.). This change in treatment protocol is necessary because the only FDA-approved intravenous (IV) antimalarial drug in the U.S., quinidine, has been discontinued by the manufacturer and will no longer be available. As of April 2019, artesunate, … Continue reading CDC: Artesunate Now First-Line Treatment for Severe Malaria in the United States →